Dendritic cells (DC) are professional antigen-presenting cells playing a central role in the induction of antigen-specific cytotoxic T-lymphocytes (CTL). We analyzed the efficiency of tumor RNA transfection into DC using different sources of RNA as well as delivery strategies including electroporation, lipofection and CD71-receptor-based delivery. To evaluate the sensitivity of these approaches, we utilized in vitro transcribed enhanced green fluorescence protein (EGFP)-RNA and whole tumor RNA from EGFP-transfected renal cell carcinoma cell line N43. We demonstrate that electroporation was the most effective way yielding about 30% EGFP positive cells while less than 1% of DC expressed EGFP using the transferrin receptor transfection system. Delivery of RNA with liposomes resulted in 17.5% of EGFP positive cells depending on the RNA amount. However, when these approaches were applied to transduce DC with RNA derived from the A498 cell line for T-cell priming, tumor-specific CTL could be induced using all delivery strategies suggesting that this technology has the potential to induce cytotoxic T-cell response even when low level of antigen is delivered. Furthermore, we demonstrate that amplification of whole tumor messenger RNA (mRNA) as well as the use of total instead of purified mRNA can be utilized for stimulating tumor-specific CTL responses.
Introduction
Dendritic cells (DC) are the most powerful antigenpresenting cells that induce and maintain primary immune responses in vitro and in vivo.
1,2 The development of protocols for ex vivo generation of DC provided a rationale to design and develop DC based vaccination studies for the treatment of infectious and malignant diseases (reviewed in Bubenik 3 and Brossart et al 4 )
. [5] [6] [7] The efficacy of antigen loading and delivery into DC is pivotal for the optimal induction of T-cell-mediated immune responses.
DC can be pulsed with synthetic peptides derived from known tumor-associated antigens. [8] [9] [10] However, the application of antigenic peptides is limited for the use in patients who express a defined specific HLA haplotype. Moreover, using MHC class I restricted peptides ignores the important role of MHC class II restricted T-helper cells in initiating and maintaining an effective immune response.
Another approach is to use full-length proteins as antigen, thus allowing the induction of immune responses against different epitopes that could be potentially restricted by multiple HLA-alleles. 11, 12 An alternative strategy is gene-based delivery of specific tumor-associated antigens (TAA) into DC that does not require prior knowledge of the patient's HLA type or the relevant T-cell peptide epitope. DC can be transduced with recombinant viruses such as retroviral or adenoviral vectors or transfected with DNA coding for a specific tumor antigen. [13] [14] [15] [16] Furthermore, other approaches utilizing whole tumors as a source of antigen have been developed using DC loaded with tumor lysates, dying tumor cells (apoptotic bodies, necrotic cells) or fused with tumor cells. [17] [18] [19] [20] [21] Recently, it was shown that DC transfected with RNA coding for a TAA or even whole tumor messenger RNA (mRNA) are able to induce potent antigen and tumorspecific T-cell responses directed against multiple epitopes. The latter technique does not require the definition of the TAA or HLA haplotype of the patients and has the potential of a broad clinical application. 22, 23 Such a polyvalent vaccine may reduce the probability of a clonal tumor escape and elicit CTL responses directed against naturally processed and presented immunodominant tumor antigens. Additional targeting of HLA class II restricted epitopes may further amplify and prolong the induced T-cell responses. In contrast to other whole-tumor vaccine approaches using tumor cell lysates, fusions of DC with tumors or dead cells that are limited by the requirement of large amounts of tumor samples, RNA-transfected DC could be applied even in patients with small tumors. The demonstration that RNA amplified from few tumor cells can be used for DC transfections and is very effective in stimulating CTL and anti-tumor immunity would allow treatment of patients with low tumor burden. 24 In our study, we analyzed the efficiency of tumor RNA transfection into DC using different RNA delivery strategies (electroporation, cationic liposomes and a transferrin receptor-based delivery system) and sources of RNA (total RNA, purified mRNA or amplified RNA). To evaluate the sensitivity of these different approaches, we utilized in vitro RNA-transcripts from a vector coding for the enhanced green fluorescence protein (EGFP) and RNA isolated from the renal cell carcinoma (RCC) cell line N43 that was transfected with an EGFP vector. We demonstrate that even low level of antigen delivery into DC, as judged by reporter gene expression, may lead to induction of antigen-specific cytotoxic T-lymphocytes (CTL) responses.
Furthermore, we established a protocol for the unspecific amplification of whole tumor mRNA. To test the efficacy of this RNA approach, we transfected DC with equal amounts of native or in vitro amplified whole tumor mRNA derived from the EGFP transfected N43 RCC cells. When whole tumor mRNA or amplified RNA was used for DC transfection, the native RNA showed a slightly higher expression of the EGFP that persisted between 30 and 40 h after transfection. In line with these results, the native mRNA appeared to be somewhat more effective than the amplified mRNA product in stimulating CTL responses.
Results

EGFP expression after transfection of DC with EGFP in vitro transcript using different methods of RNA transfection
To compare the efficiency of different methods for RNA delivery into DC, we transfected DC by electroporation, lipofection or CD71-mediated endocytosis. As shown in Figure 1 , DC generated from peripheral blood monocytes express CD71 (transferrin receptor) that can be upregulated upon stimulation with TNF-a (Figure 1b) . Electroporation and lipofection were performed with immature DC, CD71-mediated endocytosis was performed with immature and mature DC (after incubation for 24 h with 10 ng/ml TNF-a). Increasing amounts of EGFP in vitro transcript (EGFP-IVT; 2.5 -20 mg/10 6 DC) were used for transfection to assess the potential impact of the RNA amounts on the transfection efficiency. As shown in Figure 2 , electroporation proved to be the most efficient method of RNA delivery into DC yielding EGFP expression in approximately 29% of cells when 2.5 mg EGFP-IVT/10 6 DC were used (Figure 2a ). Lipofection turned out to be another feasible method, however, significantly inferior to electroporation. EGFP expression was found in approximately 7% of cells when 2.5 mg EGFP-IVT/10 6 DC were used (Figure 2b ). Increasing the amount of RNA used for transfection to 20 mg EGFP-IVT/10 6 DC upregulated the EGFP expression to approximately 17.5%, showing that there might be a positive correlation between RNA amounts and transfection efficiency (Figure 2c ). CD71-mediated endocytosis was significantly less potent as a method for RNA delivery into DC. When immature DC were used, no EGFP expression was detectable even when 20 mg EGFP-IVT/10 6 DC were utilized (data not shown). In mature DC (in which CD71 expression is upregulated to approximately 45% upon treatment with TNF-a as demonstrated in Figure1), no EGFP expression was detectable when 2.5 mg EGFP-IVT/ 10 6 DC were used (data not shown). Elevating the amount of used EGFP-IVT to 20 mg/10 6 DC showed a low EGFP expression in approximately 1% of the cells (Figure 2d ).
In the next set of experiments we compared the efficacy of RNA-transfected DC using these three different RNA delivery approaches to induce antigenspecific CTL in vitro.
CTL induction by DC transfected with tumor mRNA using different methods for RNA delivery
In these experiments, we used tumor mRNA derived from the RCC cell line A498 and peripheral blood monocytes from a healthy HLA-A2 positive donor. was performed on day 6 after adherence using an FITC-labeled monoclonal anti-CD71 antibody (black overlay). Appropriate mouse IgG isotypes were used as controls (thin lines). DC were incubated in 50 mM deferrioxamin (DFA) to upregulate CD71 expression prior to immunostaining. Crrelease assay. As shown in Figure 3 , DC transfected with all three different methods proved to possess the potential to induce CTL specific against the RCC cell line A498. Cytotoxic activity was specifically directed against the A498 cells, whereas all control target cell lines (HCT116, Croft, SK-OV-3 and ACHN) were spared. These results demonstrate that apparently no correlation exists between the level of reporter gene expression and biological function of the transfected DC and that even a low transduction efficiency may be sufficient to induce an anti-tumor CTL response.
CTL induction using DC transfected with total tumor RNA or tumor mRNA
In a clinical setting, the availability of tumor tissue for RNA isolation is frequently limited and isolation of mRNA, which normally constitutes only about 1-5% of total RNA, is an additional procedural step that might harm the very sensitive mRNA with respect to its biologic activity. Hence, we examined whether there is a detectable difference between DC transfected with whole total tumor RNA instead of whole tumor mRNA with respect to their capacity to induce tumor-specific CTL. DC were electroporated with 2.5 mg total tumor RNA/10 6 DC or 2.5 mg tumor mRNA/10 6 DC derived from the RCC cell line A498 (Figure 4a ) on day 6 after adherence as described above and used for induction of CTL. To analyze the feasibility of this approach, we in addition performed these experiments with another RCC , whereas mature DC were used in c. After electroporation or lipofection, DC were incubated with 10 ng/ml TNF-a for 24 h and used as APC for CTL induction. One restimulation was performed using similarly transfected DC after 7 days of culture. Cytolytic activity was determined on day 5 after restimulation in a standard 51 Cr-release assay. ACHN, Croft, HCT116 and SK-OV-3 were used as control cell lines. Cr-release assay. Both, DC transfected with total tumor RNA and DC transfected with tumor mRNA, were able to induce a tumor-specific CTL response in vitro. As shown in Figure 4a and b, there was no difference in cytolytic activity of the induced CTL when tumor total RNA or tumor mRNA was used again indicating that even low amounts of tumor-specific mRNA may induce a tumor-specific CTL response. To further verify the specificity of the induced CTL in an autologous setting, we used autologous DC transfected with the total tumor RNA derived from the A498 or MZ1257 cells as targets. Both CTL lines recognized DC transfected with the corresponding tumor RNA whereas they spared DC transfected with the irrelevant EGFP-IVT RNA. Interestingly, while the induced CTL did not lyse tumor cells used as a control, there was a strong crossreactivity for the A498 and MZ1257 cell lines, suggesting that there are shared tumor antigens presented by both RCC cell lines.
Unspecific amplification of whole tumor RNA
Recently, it has been shown that whole tumor mRNA can be amplified with no loss of biological function. 24 We made use of this protocol with some modifications with the goal to generate unlimited amounts of whole tumor mRNA for the transfection of DC. To analyze the integrity and size distribution of the different RNA species used for transfection, total RNA, mRNA and in vitro amplified RNA were subjected to denaturating formaldehyde agarose gel electrophoresis (data not shown).
In order to compare the efficiency of DC transfection with native or in vitro amplified tumor RNA and to gain more evidence for the biological activity of in vitro amplified mRNA samples, we transfected immature DC with native or amplified whole tumor mRNA isolated from the RCC cell line N43 that was transfected with an EGFP vector (N43-EGFP). Electroporation of DC was performed on day 6 after adherence as described above using 5 mg native N43-EGFP mRNA/10 6 DC or 5 mg amplified N43-EGFP mRNA/10 6 DC. EGFP expression was assessed by flow cytometric analysis at various time points after transfection (6-96 h) as described above. As shown in Figure 5 , EGFP expression in transfected DC could be detected shortly after transfection with native ( Figure 5a ) or amplified (Figure 5b Figure 5a) ; however, the expression kinetics were similar.
CTL induction using DC transfected with native tumor mRNA or amplified tumor mRNA
To further evaluate the biological activity of in vitro amplified whole tumor mRNA, we transfected DC with native or amplified whole tumor mRNA isolated from the RCC cell line A498 and compared their ability to induce a tumor-specific CTL response. Immature DC were electroporated on day 6 after adherence with 2.5 mg native or amplified A498 whole tumor mRNA/10 6 DC. Cytotoxic activity of the induced CTL was assessed 5 days after restimulation in a standard 51 Cr-release assay. As shown in Figure 6 , DC electroporated with . However, the application of DC in most cases is limited by the restricted number of known tumor-associated antigens, the use in patients who express a defined specific HLA haplotype or due to a low tumor burden, which does not allow to obtain sufficient material for vaccine preparation.
Recently, it was shown that RNA derived from tumor cells or plasmids coding for a tumor antigen can be delivered into DC and induce an antigen-specific CTL response. Several laboratories were able to demonstrate that this approach is feasible for tumors like colorectal cancer, prostate cancer or RCCs. [25] [26] [27] Moreover, the demonstration that amplified tumor-derived RNA is also applicable for DC transfections and CTL induction opened treatment options even for patients with low tumor burden. 24 In our study, we analyzed different strategies to transduce DC with tumor RNA and found, in line with a previous report, that electroporation was the most effective approach to deliver RNA into DC as compared with lipofection or receptor-mediated RNA endocytosis. 28 However, even the transferrin receptor system for RNA uptake, which possesses a low transduction efficacy, allowed us to induce tumor-specific CTL against the RCC tumor cell line A498, thus suggesting that even low level of antigen delivery, as judged by reporter gene expression, may lead to induction of antigen-specific CTL responses. These results could be related to the sensitivity of flow cytometry in detecting protein expression in DC after nucleic acids delivery, as we observed in our previous studies when murine DC were transduced with recombinant viruses containing the lacZ gene as a model antigen. 14 The transduction efficiency of DC was 10-30% when flow cytometry was used to determine the reporter gene expression. However, when b-galactosidase-specific CTL were utilized to detect the presentation of galactosidase-protein-derived peptides, almost all transduced DC were lysed, suggesting that CTL are more sensitive and low amounts of the protein that can not be detected by flow cytometry can generate sufficient numbers of antigenic peptides to be recognized by T-lymphocytes. Alternatively, it may be reasoned that part of the proteins synthesized after RNA transduction is not biologically functional due to degradation or incomplete sequence and is therefore not detected by flow cytometry. Nevertheless, these protein fragments may enter the antigen processing and presentation pathway of DC to generate antigenic peptides for the induction of T-cell responses.
The rate of protein synthesis and degradation might also depend on the method used for transfection as each approach might deliver the RNA to different cell compartments (electroporation to the cytosol, receptormediated endocytosis to the lysosome). 29 One major limitation of this vaccination approach in clinical trials could be the limited number and size of available tumor samples. We therefore established a protocol for the unspecific amplification of whole tumor mRNA. To test the efficacy of this RNA approach, we transfected DC with equal amounts of native or in vitro amplified whole tumor mRNA derived from the EGFPtransfected N43-RCC cells. The transfection of DC with whole tumor mRNA or amplified RNA showed a slightly higher expression of the EGFP when native RNA was applied with a maximum of EGFP expression at 40 h post-transfection, thus demonstrating that the amplification of RNA does not compromise the quality and biological function of the obtained whole tumor RNA and the resulting proteins. To analyze the potency of amplified and native RNA to elicit a specific CTL response in vitro we utilized RNA isolated from the RCC cell line A498. The obtained CTL specifically lysed the A498 tumor cells in a standard 51 Cr-release assay. Another interesting and important observation in our study is the cross-reactivity of the CTL generated with RNA isolated from different RCC cell lines indicating that there are tumor-associated antigens expressed and shared by different RCC cells. These results might have implications for the development of immunotherapeutic strategies. To address the possible alloreactivity of the induced T-cells, we used different allogenic tumor cell lines as controls in the 51 Cr-release assay and these cells were not lysed by the CTL. Furthermore, we performed experiments using autologous DC transfected with the corresponding tumor RNA or an irrelevant EGFP-IVT RNA. Only autologous DC transfected with the tumorderived RNA were recognized by the induced cytotoxic T-cells, thus confirming the specificity of the CTL.
In summary, our results extend previous observations that RNA-transfected dendritic cells are capable of stimulating anti-tumor CTL responses. We additionally demonstrate that even very low levels of gene expression can result in antigen-specific CTL induction. E:T E:T % Specific Lysis Native A498 mRNA Amplified A498 mRNA b a Figure 6 CTL induction using DC transfected with native tumor mRNA or amplified tumor mRNA. Immature DC (day 6) were electroporated with 2.5 mg native (a) or in vitro amplified (b) A498 derived whole tumor mRNA. After further maturation with 10 ng/ml TNF-a for 24 h, DC were used as APC for in vitro CTL induction. Cytolytic activity was determined on day 5 after restimulation with similarly transfected DC in a standard 51 Cr-release assay. ACHN, Croft, HCT116 and SK-OV-3 were used as control cell lines.
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Materials and methods
Tumor cell lines
Tumor cell lines used in the experiments were grown in RP10 medium (RPMI 1640 supplemented with 10% heatinactivated fetal calf serum (FCS), 2 mmol/l L-glutamine, 50 mmol/l 2-mercaptoethanol, and antibiotics). The following tumor cell lines were used: N43 (RCC, HLA-A1/-), A498 (RCC, HLA-A2/-; B8/-), MZ1257 (RCC, HLA-A2/-), HCT116 (colon carcinoma, HLA-A2/-), Croft (EBVimmortalized B-cell line, kindly provided by O J Finn (Pittsburgh, PA, USA), HLA-A2/-; B7/8; Cw7/-), SK-OV-3 (ovarian cell line, HLA-A3/68; B18/35), and ACHN (RCC, HLA-A26/-).
Cell isolation and generation of DC from adherent peripheral blood mononuclear cells Generation of DC from peripheral blood monocytes was performed as described previously. 6, 7 In brief, peripheral blood mononuclear cells (PBMC) were isolated by Ficoll/ Paque (Biochrom, Berlin, Germany) density gradient centrifugation of heparinized blood obtained from buffy coat preparations of healthy volunteers from the blood bank of the University of Tü bingen. Cells were seeded (1 Â 10 7 cells/3 ml/well) into 6-well plates (Corning, Cambridge, MA, USA) in RP10 medium (RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM Lglutamine, 50 mM 2-mercaptoethanol, and antibiotics). After 2 h of incubation at 371C, non-adherent T cells were removed, and the adherent blood monocytes were cultured in RP10 medium supplemented with the following cytokines: human recombinant GM-CSF (Leukomax; 100 ng/ml; Novartis, Nü rnberg, Germany) and interleukin 4 (IL-4; 1000 IU/ml; Genzyme, Cambridge, MA, USA) for the generation of immature DC. For maturation, DC were additionally cultured with tumor necrosis factor-a (TNF-a; 10 ng/ml; Genzyme) for 24 h after day 6. The phenotype of DC was analyzed by flow cytometry (FACSCalibur, Becton Dickinson, Heidelberg, Germany) after 7 days of culture.
Immunostaining
Cell staining was performed using FITC-or PE-conjugated mouse monoclonal antibodies against CD86, CD40 (PharMingen, Hamburg, Germany), CD80, HLA-DR, CD54, CD14, CD71 (transferrin receptor) (Becton Dickinson), CD83 (Coulter-Immunotech, Hamburg, Germany) and CD1a (OKT6; Ortho Diagnostic Systems, Seattle, WA, USA). Appropriate mouse IgG isotypes were used as controls (Becton Dickinson). The samples were analyzed by flow cytometry (data not shown).
Transfection of N43 cells with pEGFP-N1
The RCC cell line N43 was cultured and expanded in RP10 medium. The cells were transfected with the expression vector pEGFP-N1 (BD Biosciences Clontech, Heidelberg, Germany) using FuGENE 6t transfection reagent (Roche Molecular Biochemicals, Mannheim, Germany) according to the protocol provided by the manufacturer. For positive selection of stable transfectants, the cells were selected and cultured in RP10 medium containing the antibiotic geneticin (Invitrogen, Karlsruhe, Germany) at a concentration of 500 mg/ml.
The new EGFP expressing cell line was named 'N43-EGFP'.
Generation of EGFP mRNA by in vitro transcription
For the generation of EGFP mRNA, the plasmid pSP64 Poly(A) EGFPII (generously provided by VFI Van Tendeloo, Antwerp, Belgium), which allows in vitro transcription under the control of an SP6 promoter, was used. The plasmid was linearized using the restriction enzyme NdeI (MBI Fermentas, St Leon-Rot, Germany) and in vitro transcribed with the SP6 Cap Scribe TM kit (Roche) according to the protocol provided by the manufacturer. Purification of in vitro transcripts (IVTs) was performed with RNeasy TM Mini anion-exchange spin columns (Qiagen, Hilden, Germany) according to the RNA clean-up protocol provided by the manufacturer. IVT were routinely checked by formaldehyde/ agarose gel electrophoresis for size and integrity and stored at À801C in small aliquots.
RNA isolation
Total RNA was isolated from tumor cell lysates using RNeasy TM Maxi anion-exchange spin columns (Qiagen) according to the protocol for isolation of total RNA from animal cells provided by the manufacturer. mRNA was prepared from total RNA utilizing the MACS mRNA Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) following the instructions of the manufacturer. Quantity and purity of RNA was determined by UV spectrophotometry. RNA samples were routinely checked by formaldehyde/agarose gel electrophoresis for size and integrity and stored at À801C in small aliquots.
Unspecific amplification of messenger RNA
Unspecific mRNA amplification was done with some modifications as described by Boczkowski et al. 24 Firststrand cDNA synthesis and long distance (LD) PCR were performed using the SMARTt PCR cDNA Synthesis Kit (BD Biosciences Clontech) with some modifications. Briefly, 1 mg of total RNA was subjected to cDNA synthesis. Differing from the protocol of the manufacturer, an oligonucleotide containing the bacteriophage promoter T7 was used as 'template-switch oligo' (5 0 -CGCGCGCGCTAATACGACTCACTATAGGGG-3 0 ). 30 After termination of the reaction, the samples were diluted by adding 90 ml of TE buffer. The first-strand reaction product was then amplified by LD PCR. The 100-ml reaction contained 10 ml of the diluted first-strand cDNA, 20 pmol of the CDS-PCR primer supplied with the kit and 20 pmol of a self-designed 'T7-PCR-primer' (5 0 -GCGCGCGCTAATACGACTCACTAT-3 0 ). The reaction conditions were as indicated by the supplier. The temperature profile was as follows: an initial denaturation step at 951C and 20 cycles at 951C for 15 s, 601C for 30 s, 681C for 7 min and a final extension at 681C for 10 min. The LD PCR product was purified using the QIAquickt PCR Purification Kit (Qiagen). For in vitro transcription of the LD PCR product, the mMESSAGE mMACHINEt T7 Kit (Ambion, Huntingdon, UK) was used, following the instructions of the manufacturer. Five microliters of the purified LD PCR product was subjected to a standard reaction containing an additional microliter of GTP. After 2 h of incubation at 371C, the DNA template was removed by DNase I digestion and RNA loaded dendritic cells induce antitumor CTL F Grünebach et al the capped RNA in vitro transcript was purified by the RNeasy TM clean-up protocol (Qiagen). Quantity and purity were determined by UV spectrophotometry.
All RNA samples used for DC transfection were resolved on 1% standard formaldehyde/agarose gels and stained with ethidium bromide for visualization under UV light to check their integrity and size distribution.
Electroporation of DC
Prior to electroporation on day 6, immature DC were washed twice with serum-free X-VIVO 20 medium (BioWhittaker, Walkersville, MD, USA) and resuspended to a final concentration of 2 Â 10 7 cells/ml. Subsequently, 200 ml of the cell suspension was mixed with the respective species and amount of RNA and electroporated in a 4 mm cuvette using an Easyject Plust unit (Peqlab, Erlangen, Germany). The physical parameters were: voltage of 300 V, capacitance of 150 mF, resistance of 1540 O and pulse time of 231 ms. After electroporation, the cells were immediately transferred into RP10 medium and returned to the incubator. The viability of the cells was more than 80% after electroporation.
Lipofection of DC
Lipofection of immature DC was performed on day 6 using the cationic lipid Unifectin (generously provided by I Hoerr, Tü bingen, Germany). Twelve hours prior to lipofection, DC were collected and resuspended in RP10 medium to a final concentration of 5 Â 10 5 DC/ml. This cell suspension was subsequently distributed on 6-well plates (1 ml/well). Protamine was added to the RNA solution in a mass:mass ratio of 1:1. This RNA-enhancer solution was then diluted with lipofection buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) to a final volume of 100 ml. Unifectin was applied in the following ratio: 3 mg Unifectin/mg RNA. The appropriate amount of Unifectin was diluted with lipofection buffer to a final volume of 100 ml. After a 5 min incubation period, the Unifectin was slowly added to the RNA-enhancer solution. After another 10 min incubation period, the transfection cocktail was slowly added to the cell suspension prepared in 6-well plates. After lipofection the cells were incubated at 371C. [31] [32] [33] Transferrin receptor-mediated endocytosis DuoFect TM (Quantum Appligene, Carlsbad, CA, USA) was used for transferrin receptor (CD71)-mediated endocytosis of immature and mature DC. The surface CD71 expression on immature and mature DC was determined by immunostaining with FITC-labeled monoclonal anti-CD71 antibody. The manufactureŕs protocol for DNA transfection was adapted for RNA transfection as follows. DC were collected on day 5 (24 h prior of transfection) and resuspended in fresh RP10 medium containing 50 mM deferrioxamine (and 10 ng/ml TNF-a for mature DC). Twenty-four hours later, DC were collected by centrifugation and resuspended in RP10 (supplemented with deferrioxamine and TNF-a for mature DC as mentioned above). The cell suspension was then distributed into 6-well plates (5 Â 10 5 DC/ well). The transfection was performed according to the manufactureŕs protocol using an N/P ratio (molar ratio of nitrogen (polyethylenimine) and phosphate groups (RNA)) of 3.2. After transfection, DC were returned to the incubator. After an incubation period of 4 h, the cells were washed twice with RP10 medium to remove the transfection medium and resuspended in regular RP10 medium.
EGFP analysis by flow cytometry
EGFP-transfected DC were checked for EGFP 6-96 h after transfection by flow cytometric analysis (FACSCalibur, Becton Dickinson). Briefly, 2 Â 10 5 cells were washed once with 5 ml phospate-buffered saline (PBS) and were then resuspended in 200 ml of PBS supplemented with 0.5% bovine serum albumin (BSA). Gating was performed on cells exhibiting a large forward scatter (FSC) and side scatter (SSC) profile in order to allow exclusion of contaminating autologous lymphocytes. Gated DC were then evaluated for EGFP expression. As a control non-transfected DC were used.
Induction of tumor-specific CTL using DC transfected with tumor RNA DC were transfected with RNA using different methods (as described above) on day 6. After transfection, DC were incubated for 24 h in RP10 medium containing 10 ng/ml TNF-a for maturation of DC. For CTL induction, 5 Â 10 5 DC (transfected with tumor RNA) were incubated with 2.5 Â 10 6 autologous PBMC in RP10 medium. Additional DC transfected with RNA were stored at À801C to be used later for restimulation. After 7 days of culture, cells were restimulated with autologous RNA-transfected DC and 1 ng/ml human recombinant IL-2 (Genzyme) was added on days 1, 3 and 5. The cytolytic activity of induced DC was analyzed on day 5 after restimulation in a standard 51 Cr-release assay.
CTL assay
The standard 51 Cr-labeled release assay was performed as described. 7 Target cells were labelled with 51 Cr sodium chromate in RP10 medium for 1 h at 371C. Cells (10 4 ) were transferred to a well of a round-bottomed 96-well plate. Varying numbers of CTL were added to give a final volume of 200 ml and incubated for 4 h at 371C. At the end of the assay, supernatants (50 ml/well) were harvested and counted in a b-plate counter (MicroBeta, Perkin-Elmer Wallac, Freiburg, Germany). The percentage of specific lysis was calculated as: 100 Â (experimental release À spontaneous release/ maximal release -spontaneous release). Spontaneous and maximal releases were determined in the presence of either RP10 medium or 1% Triton X-100, respectively.
